TARGET-BASED METHOD FOR HIGH-THROUGHPUT AND SUBCLASS SPECIFIC IgG GLYCAN PROFILING IN HUMAN PLASMA
US-2024353417-A1 · Oct 24, 2024 · US
Methods and compositions for inhibiting CD32b expressing cells
US9260523B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9260523-B2 |
| Application number | US-201113301627-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2011 |
| Priority date | May 30, 2007 |
| Publication date | Feb 16, 2016 |
| Grant date | Feb 16, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
First claim
Opening claim text (preview).
We claim: 1. A method of activating at least one B cell or dendritic cell comprising contacting the cell with an immunoglobulin comprising an Fc region that binds FcγRIIb on the cell surface with enhanced affinity as compared to a parent immunoglobulin and at least one Fv region that binds CD40 on the cell surface, wherein the immunoglobulin comprises Fc substitutions S267E and L328F as compared to a parent Fc region, wherein the numbering is according to the EU index, as in Kabat.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9260523B2 cover?
- The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
- Who is the assignee on this patent?
- Chu Seung Yup, Desjarlais John R, Karki Sher Bahadur, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).